Third, the exclusion of patients with insulin use and eGFR <45 mL/min/1.73 m2 restricts generalizability to broader T2DM populations who may particularly benefit from SGLT2i therapy based on recent trials. Here, INS is linked to type 2 diabetes mellitus.